

TPW


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on

INFORMATION DISCLOSURE STATEMENT
Examining Group 1646
Patent Application
Docket No. UF-530XT
Serial No. 10/660,069

21 November 2006

Barbara S. Kitchell

Barbara S. Kitchell, Patent Attorney



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Applicants : Ronald L. Hayes, Ka-Wang (Kevin) Wang, Brian R. Pike
Serial No. : 10/660,069
Filed : September 11, 2003
Conf. No. : 7655
For : Analyzing Nerve Cell Damage

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed. However, applicants have not submitted copies of the U.S. patents or published U.S. Patent Applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.


Respectfully submitted,



Barbara S. Kitchell
Patent Attorney
Registration No. 33,928
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
P.O. Box 142950
Gainesville, FL 32614-2950

BSK\jgk\lkw

Attachments: Form PTO/SB/08 (3 pages)
Copies of references cited (14)



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/660,069
Filing Date	September 11, 2003
First Named Inventor	Ronald L. Hayes
Art Unit	
Examiner Name	
Attorney Docket Number	UF-530XT

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US 5,536,639	07-16-1996	Siman, et al.	all
	U2	US 5,118,606	06-02-1992	Lynch, et al.	all
	U3				
	U4				
	U5				
	U6				
	U7				
	U8				
	U9				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 95/26506	10-05-1995	Cephalon, Inc.	ALL	
	F2					
	F3					
	F4					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

Application Number

10/660,069

Filing Date

September 11, 2003

First Named Inventor

Ronald L. Hayes

Group Art Unit

Examiner Name

Attorney Docket Number

UF-530XT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	PIKE, BRIAN R., <i>et al.</i> : "Accumulation of non-erythroid alphaII-spectrin and calpain-cleaved alphaII-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats", <i>Journal of Neurochemistry</i> , September 2001, pp 1297-1306, Vol. 78, No. 6.	
	R2	NATH, RATHNA, <i>et al.</i> : "Non-erythroid alpha-spectrin breakdown by calpain and interleukin 1beta-converting-enzyme-like protease(s) in apoptic cells: contributory roles of both protease families in neuronal apoptosis", <i>Biochemistry Journal</i> , November 1, 1996, pp. 683-690, Vol. 319.	
	R3	LI, ZHAOZHAO, <i>et al.</i> : "Peptide alpha-Keto Ester, alpha-Keto Amide, and alpha-Keto Acid Inhibitors of Calpains and Other Cysteine Proteases", <i>Journal of Medicinal Chemistry</i> , October 29, 1993, pp. 3472-80, Vol. 36, No. 22.	
	R4	YOKOTA, M., <i>et al.</i> : "Three distinct phases of fodrin proteolysis induced in postischemic hippocampus - involvement of calpain and unidentified protease", <i>Stroke</i> , October 1995, pp. 1901-1907, Vol. 26, No. 10.	
	R5	NATH, RATHNA, <i>et al.</i> : "Development and characterization of antibodies specific to caspase-3-produced alpha II-spectrin 120 kDa breakdown product: marker for neuronal apoptosis", <i>Neurochemistry International</i> , 2000, pp. 351-361, Vol. 37.	
	R6	PIKE, BRIAN R., <i>et al.</i> : "Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury", <i>NeuroReport</i> , August 3, 1998, pp. 2437-42, Vol. 9, No. 11.	
	R7	ZHAO, X., <i>et al.</i> : "Maitotoxin Induces Calpain But Not Casepase-3 Activation and Necrotic Cell Death in Primary Septo-Hippocampal Cultures", <i>Neurochemical Research</i> , 1999, pp. 371-382, Vol. 24, No. 3.	
	R8	PIKE, BRIAN R., <i>et al.</i> : "Temporal Relationships Between De Novo Protein Synthesis, Calpain and Calpase 3-like Protease Activation, and DNA Fragmentation During Apoptosis in Septo-Hippocampal Cultures", <i>Journal of Neuroscience Research</i> , 1998, pp. 505-520, Vol. 52.	
	R9	GIZA, CHRISTOPHER C., <i>et al.</i> : "The Neurometabolic Cascade of Concussion", <i>Journal of Athletic Training</i> , September 2001, pp. 228-235, Vol. 36, No. 3.	
	R10	MCGINNIS, KIM M., <i>et al.</i> , "Alterations of Extracellular Calcium Elicit Selective Modes of Cell Death and Protease Activation in SH-SY5Y Human Neuroblastoma Cells", <i>Journal of Neurochemistry</i> , 1999, pps. 1853-63, Vol. 72, No. 5, Lippincott Williams & Wilkins, Inc., Philadelphia, PA.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/660,069
Filing Date	September 11, 2003
First Named Inventor	Ronald L. Hayes
Group Art Unit	
Examiner Name	
Attorney Docket Number	UF-530XT

Sheet	3	of	3
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	NATH, RATHNA, <i>et al.</i> : "Activation of apoptosis-linked caspase(s) in NMDA-injured brains in neonatal rats", <i>Neurochemistry International</i> , 2000, pp. 119-126, Vol. 36.	
	R2	BARTUS, RAYMOND T., <i>et al.</i> "Time-Related Neuronal Changes Following Middle Cerebral Artery Occlusion: Implications for Therapeutic Intervention and the Role of Calpain," <i>Journal of Cerebral Blood Flow and Metabolism</i> , November 1995, pp. 969-79, Vol. 15, No. 6, Lippincott-Raven Publishers, Philadelphia, PA.	
	R3	Supplementary Partial European Search Report	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--